Left Ventricular Global Longitudinal Strain in HER‐2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction
- 16 March 2016
- journal article
- research article
- Published by Wiley in Echocardiography
- Vol. 33 (4) , 519-526
Abstract
Aim: The combination of anthracyclines (AC) and trastuzumab (TRZ) is highly effective in patients with aggressive HER‐2 + breast cancer, but has a significant risk of cardiotoxicity (CT). Trastuzumab‐induced CT may be reversible. The aim of this study was to identify echocardiographic parameters associated with recovery of left ventricular ejection fraction (LVEF) in patients who developed CT after AC and TRZ treatment.Methods and Results: Women with newly diagnosed breast cancer treated with AC followed by TRZ and monitored with serial echocardiograms were retrospectively studied. Left ventricular end‐diastolic and systolic volumes, LVEF, and global longitudinal strain (GLS) were examined. Development and reversibility of CT were defined based on changes in LVEF according to the 2014 ASE/EACVI recommendations. Cox analysis was used to determine the association of echocardiographic variables with the subsequent development and reversibility of CT. Ninety‐five patients underwent 5 echocardiograms or more in a 17‐month (13–28 months) follow‐up period. Nineteen patients (20%) developed CT. Left ventricular volumes, LVEF, and GLS measured after AC completion identified the subsequent development of CT. Of the 19 patients with CT, the LVEF partially or fully recovered in 13 (68%). GLS at the time of CT diagnosis was associated with subsequent recovery of LVEF (P = 0.004).Conclusion: In patients with breast cancer treated with AC and TRZ who develop CT, GLS at the time of CT diagnosis is associated with subsequent recovery of LVEF and may be useful for risk stratification and to guide treatment.Keywords
This publication has 28 references indexed in Scilit:
- Chemotherapy‐related cardiomyopathy: a neglected aspect of cancer survivorshipInternal Medicine Journal, 2014
- Cardiovascular events, early discontinuation of trastuzumab, and their impact on survivalBreast Cancer Research and Treatment, 2014
- Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort StudyJNCI: Journal of the National Cancer Institute, 2012
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant TrialJournal of Clinical Oncology, 2007
- Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of ReversibilityJournal of Clinical Oncology, 2007
- Long-Term Risk of Cardiovascular Disease in 10-Year Survivors of Breast CancerJNCI: Journal of the National Cancer Institute, 2007
- Effect of Screening and Adjuvant Therapy on Mortality from Breast CancerNew England Journal of Medicine, 2005
- Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1β and Anti-erbB2Circulation, 2002
- Underlying Causes and Long-Term Survival in Patients with Initially Unexplained CardiomyopathyNew England Journal of Medicine, 2000